Sanofi Says Drug Shows Potential to Slow Diabetes in Late-Stage Trial
18 10월 2023 - 6:40PM
Dow Jones News
By Adria Calatayud
Sanofi said its Tzield drug met the primary goal of a phase 3
clinical trial, showing potential to slow the progression of a type
of diabetes in newly diagnosed children and adolescents.
The French pharmaceutical giant said Tzield demonstrated in the
trial superior beta-cell preservation compared with placebo, and
that this indicates its potential to slow the progression of Stage
3 type 1 diabetes in this population.
The trial studied the efficacy and safety of the drug in
children and adolescents aged 8-17 years, the company said.
Results for the study's key secondary goals, which included a
numerically lower mean insulin dose, weren't considered
statistically significant, Sanofi said.
Sanofi added Tzield to its portfolio through the acquisition of
Provention Bio, which was completed in April.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 18, 2023 05:25 ET (09:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sanofi (NASDAQ:SNY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
